Compare CRNX & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | GTLB |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2018 | 2021 |
| Metric | CRNX | GTLB |
|---|---|---|
| Price | $38.50 | $20.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 29 |
| Target Price | ★ $76.63 | $40.62 |
| AVG Volume (30 Days) | 1.1M | ★ 5.7M |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,039,000.00 | ★ $955,224,000.00 |
| Revenue This Year | $720.10 | $18.82 |
| Revenue Next Year | $184.67 | $15.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $25.83 | $18.73 |
| 52 Week High | $57.99 | $52.38 |
| Indicator | CRNX | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 36.72 |
| Support Level | $33.19 | N/A |
| Resistance Level | $45.32 | $50.49 |
| Average True Range (ATR) | 1.56 | 1.22 |
| MACD | 0.74 | 0.10 |
| Stochastic Oscillator | 74.69 | 26.78 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.